

Can Keep Them "Happy For Life"

By Effectively Addressing The Root Causes of Depression, Anxiety and ADHD Naturally and Safely



Indication: Clinical Dietary Management of Major Depressive Disorder

Once-a-day dosing / No age restriction

TEAM METHYLATION PRE-METABOLIZED COENZYMES AND COFACTORS: BRAIN READY INGREDIENTS

Reduced Folates

L-Methylfolate Magnesium	7mg
Folinic Acid	3.5mg

B Vitamins in their Bioactive Coenzyme Form

B12 (Adenosylcobalamin)	50mcg
B6 (Pyridoxal-5-Phosphate)	25mcg
B1 (Thiamine Pyrophosphate)	
B2 (Flavin Adenine Dinucleotide)	25mcg
B3 (Nicotinamide Adenine Dinucleotide)	25mcg
Bioperine (B Vitamin Bioenhancer)	. 500mcg
Betaine (Trimethyl Glycine)	1mg

Minerals in their Bioactive Cofactor Form

Magnesium Ascorbate	24mg
Magnesium L-Threonate	1mg
Zinc Ascorbate	1mg
Ferrous Glycine Cysteinate	1.5mg

Phospholipid Form–Brain Ready


PS-Omega-3 (Phosphatidylserine)	, EPA, DHA)	23.3mg
---------------------------------	-------------	--------

Absorption Enhancer

Energizer

METHYLATION CHART

EnLyte/EnBrace HR provides all the downstream coenzymes, cofactors, and omegas needed to normalize and balance biochemical endpoints which correlates into clinical remissions in well-controlled clinical trials. EnLyte, EnBrace HR Product Ingredients Maroon | Biochemical End Points Green




THE JOURNAL OF CLINICAL PSYCHIATRY MAY 2016

Correlation of Clinical Response With Homocysteine Reduction During Therapy With EnLyte/EnBrace HR in Patients With MDD Who Are Positive for MTHFR C677T or A1298C Polymorphism

Andrew Farah, MD

ADULT PATIENT RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY

OBJECTIVE: This study was designed to evaluate the efficacy and safety of EnLyte/EnBrace HR as monotherapy in adults with major depressive disorder (MDD) who were also positive for at least 1 methylenetetrahydrofolate reductase (MTHFR) polymorphism associated with depression and further test the hypothesis that EnLyte/EnBrace HR will lower homocysteine in a majority of clinical responding patients.



ONSET OF ACTION 2 WEEKS


EnBrace HR For The Treatment and Prevention of Depression in Women Trying to Conceive and During Pregnancy

MGH



Marlene P. Freeman, MD et al, Annals of Clinical Psychiatry February 2019 | FDA Approved

Relapse Prevention Group: MDD, But Well at Baseline Due to SSRIs/SNRIs, Drug ADs Replaced With EnBrace HR at Pregnancy



Tension/Anxiety - Depressed Mood - Irritability/Anger - Appetite Changes - Cravings - Insomnia - Social Conflict Withdrawal Feeling Overwhelmed - Hopelessness - Hot Flashes



IMedPub Journals http://www.imedpub.com

A Clearly Needed ALL-NATURAL SAFE OPTION

Clinical Psychiatry ISSN 2471-9854

Coenzyme Treatment of Childhood and Adolescent Depression and ADHD:

A Case Series

A. Farah MD, Gauri Madan MD, April 21, 2021

In Depression

- Indicated for MDD
- No Age Restriction
- Majority in Study Remitted
- No Side Effects Reported
- No Suicidal/Violent Thoughts

In ADHD

Treat "**Adjunctively**" with Stimulants to Address the "Whole Symptom Complex"

- Root Biochemical Cause
- Emotional Dysregulation
- Psychiatric Comorbidities
- Nutritional Deficiencies

"Monotherapy"

- Root Biochemical Cause
- In MTHFR SNP
- To Avoid Drug Side Effects
- During Drug Holiday

MDD Algorithm:

Andrew Farah MD, DFAPA

- 1. EnLyte 1 a day
- 2. Partial Goal, Week 3
- Add Prozac 5-10 mg. a day
- 3. Partial Goal, Week 6, Each BID

ADHD Step-Care Algorithm:

Arwen Podesta MD, DFAPA, DFASAM

- 1. EnLyte 1 a day
- 2. Partial Goal, Week 4 Add Drug Non-Stimulant Or Low Dose Drug Stimulant
- 3. Partial Goal, Week 8 Increase Drug Stimulant

ALL NATURAL SAFETY PROFILE

FDA Reported Side Effects	<u>EnLyte</u>	SSRI's	SNRI's
Weight Gain	No!	Yes	Yes
Loss of Libido, difficulty achieving erections, inability to reach orgasm	No!	Yes	Yes
Increased thoughts of suicide and aggression in adolescents & adults	No!	Yes	Yes
Drowsiness or Confusion	No!	Yes	Yes
Nervousness & Agitation	No!	Yes	Yes

Adapted from: Consumer Reports Best Buy Drugs. Using antidepressants to treat depression: comparing efficacy, safety and price. 2012

"90% of individuals with depression have lower CNS folate levels than there non depressed counterparts"

CONTRIBUTORS TO FOLATE AND OTHER B VITAMIN COENZYME DEFICIENCIES

GENETIC	CONDITIONS	DRUGS	POPULATIONS	
MTHFR SNPS	Gastric Bypass	Lamictal	Pregnant	
C677T	Celiac Disease	Metformin	Post Partum	
A1298C	Kidney Disease	Methotrexate	Breast Feeding	
	Liver Disease	Corticos teroids	Elderly	
	Diabetes	NSAIDs	ADHD/ASD	
Family History	Cancers	Antibiotics	Hispa nic	
Mental Illness	Anemias	Anticonvuls <mark>ants</mark>	Alc <mark>oho</mark> lic	
Miscarriages	Crohn's	Oral	Drug Addiction	
Birth Defects	Psoriasis	Contraceptives	Smoke rs	
Heart Disease	Eczema	Cholesterol	C <mark>hild</mark> Be <mark>ari</mark> ng Age	
Diabetes		Lowering	Depres sion	
	Infection	Diuretics	Contaminants	
B-Vitamin	Viral / Bacterial	H2 Antagonists	Low Socio	
Non Tested		Phenytoin	Economic	
Methylation	Cardiac	SSRIs	Poor Nutrition	
Polymorphisms	Epilepsy	SNRIS	Vegetarian	
Suspected	Seizures	Aspirin	Stressed	

EnLyte / EnBrace HR Meet The Ingredient Requirements For American Psychiatric Association

Complementary and Alternative Medicine in Major Depressive Disorder: The American Psychiatric Association Task Force Assessment of Evidence, Challenges and Recommendations

APA Taskforce: Marlene Freeman MD, Maurizio Fava MD, J Lake MD, MH Trivedi MD, David Mischoulon MD

"Folate: Folate and several related compounds have received study to ascertain if there is a potential role in the treatment of MDD. There is consistent and growing evidence of a role for various folate forms in the prevention and treatment of depression. Studies to date demonstrate efficacy of augmentation of antidepressants with folic acid, folinic acid (leucovorin), and 5-methyltetrahydrofolate (5-MTHF). Similar findings may be attributable to the fact that these folate forms share an interconversion potential in the complex set of pathways that comprise the one-carbon or methylation cycles. These reactions, which in turn depend on B12 and homocysteine availability, are postulated to exert an antidepressant effect by impacting the synthesis of neurotransmitters such as serotonin, dopamine, and norepinephrine."



#2 (

"Folate augmentation should be used to enhance antidepressant efficacy from the start of treatment or, for patients who are already on antidepressant treatment, to convert partial or non-responders into responders or remitters."

"Folate and methylfolate monotherapy may benefit certain depressed populations."



"APA advocates for, folate/methylfolate with B12 and Omega 3s as monotherapy or augmentation strategy for MDD."

Full report available upon request.

MDD Algorithm: Andrew Farah MD, DFAPA

Adult MDD/Mild – Moderate

EnLyte/EnBrace HR 1 a Day

Partial/non-response at 4 weeks, Enlyte/EnBrace HR twice a day

Partial/non-response add SRI or SNRI, continue EnLyte/EnBrace HR (BID)

Adult MDD/Severe

EnLyte/EnBrace HR with SRI or SNRI [from Day 1]

Partial/non-response at 3 weeks - increase Enlyte/EnBrace HR to BID /

increase dose of antidepressant @ clinician discretion

Partial/non-response 6 weeks - Enlyte/EnBrace HR BID/switch AD/or

escalate dose at discretion

No response 12 weeks to BID Enlyte/EnBrace HR and >3

ADs: TMS or ketamine + Enlyte/EnBrace HR

MDD in **Pregnancy**

EnLyte/EnBrace HR 1 a Day

Partial/non-response - 3 weeks Enlyte/EnBrace HR BID

Partial/non-response 6 weeks- continue Enlyte/EnBrace HR,

add SRI [Not Paxil/Wellbutrin]

Partial/non-response 9 weeks: cont. Enlyte/EnBrace HR with new AD or with TMS

HOW TO PRESCRIBE



USE OUR ONLINE PRESCRIBER FORM

Visit www.enlyterx.com and click on "Prescribe Now!" Fill in prescriber and patient information and then hit"submit"



WE WILL OFFER YOUR PATIENT THEIR FIRST <u>60 DAYS FOR \$60 (2 BOTTLES AT \$29.95 EACH)</u>

We will also provide them with the insurance steps and help determine the most cost-effective option moving forward.



IF IT'S COVERED ON INSURANCE, WE WILL CONTACT YOUR OFFICE WITH PRESCRIBING INFORMATION

If your patient does not have coverage or has a high co-pay, we will offer our discounted cash-pay option for EnLyte (ENL). No further action is needed from your office.

INSURANCE COVERAGE

MEDICAID COVERAGE:

LOUISIANA: EnBrace HR / EnLyte Preferred on La MCD with no PA **TEXAS:** EnLyte Preferred on Texas MCD with no PA **SOUTH DAKOTA:** Enlyte is Preferred on SD MCD. **NEW YORK:** EnBrace HR Preferred.

COMMERCIAL COVERAGE:

COMMERCIAL COVERAGE IS DEPENDENT ON INDIVIDUAL INSURANCE PLANS

DISCOUNTED CASH PAY OPTION:

If EnLyte is not covered on an individual insurance plan, patients have the option of purchasing the non-prescription version called "ENL" through Direct Value Dispense at an affordable cost. Call 985.629.5825 For More Information.

27. Chambers et al., SSRI and Risk of Persistent Pulmonary Hypertension of the 8105, 20LA , zizylana-atemic review, meta-analysis, AJOG, 2018 26. Mararwa et al., Prenatal exposure to SSRIsand SURIsand risk for pulmonary

28. Kieviet et al., Use of antidepressants during pregnancy in The Netherlands: Newborn, The New England Journal of Medicine, 2011

Childbirth, 2017 observational study into post-partum interventions, BMC Pregnancy &

Zf02 ,tasl amotqmy2 ob pnoJ woH :noitstqsbA lstsno9/ 29. MGH Center for Women's Health, womensmentalhealth.org, SSRIsand Poor

Offspring, BMJ, 2017 30. Liu et al., Antidepressant Use During Pregnancy and Psychiatric Disorders in

31. Lugo-Candelas et al., Association Between Brain Structure and Connectivity

32. WebMD. www.webmd.com, pregnancy-and-antidepressants, 2018 in Infants and Exposure to SSRIsDuring Pregnancy, JAMA Pediatrics, 2018

33. FDA AAppendix MIH, Antidepressant Drug Labels for Pregnant and Postpartum Women, 2014

34. EnBrace HR Pl, FDS Daily Med, Dec. 2018

35. Turgal et al. MTHFR Polymorphisms and Pregnancy Outcome, PMC 6138472, Sept. 2018

36. Duprey Robert P. MTHFR Gene Polymorphism positive treatment-resistant depression, Neuropsychiatry 2019

37. ImbardA, Benoist JF, BlomHJ. Neural tube defects, folic acid and methylation. Int J Environ Res Public Health. 2013

38. Obeid R, HolzgreveW, PietrzikK. Is 5-methyltetrahydrofolate an alternative to folic acid for the prevention of neural tube defects? J. Perinatal Med, 2013

39. Greenberg JA, Bell SJ, Guan Y, Yu YH. Folic Acid supplementation and pregnancy: more than just neural tube defect prevention. Rev ObstetGynecol. 2011

40. NIH, Folate Fact Sheet for Professionals, 2022

41. MGH Center for Women's Mental Health, Folic Aid Supplements Before and After Conception: Prevention of Autism, 2022

42. BjorkM, Riedel B, SpigsetO, VeibyG, Kolstad E, DaltveitAK, GilhusNE. Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in

Children Exposed to Antiepileptic Drugs In Utero. JAMA Neurol. 2018 Feb

43. Sah AK, Shreatha U, Joshi P, LakhaR, Shreatha S, Sharma L, Chandra A, Singh U, Kc Y, RijalB. Association of parental methylenetetrahydrofolate reductase (MTHFR)

C677T gene polymorphism in couples with unexplained recurrent pregnancy loss. BMC Res Notes. 2018 Apr

44. MGH Center for Womens' Mental Health Folic Acid and Risk of Perinatal Depression: Is there an Association? 2012